Who Won It

Contract award · 22 Jan 2021

Purchase of 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours

The Royal Marsden NHS Foundation Trust awarded “Purchase of 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours” to Advanced Accelerator Application for £4.5m on 22 Jan 2021. Awarded without open competition.

No competitionMedical equipment & pharmaceuticalsLondon

BuyerThe Royal Marsden NHS Foundation Trust
Value £4.5m
WinnerAdvanced Accelerator Application

Awarded without open competition

Awarded without open competition. The buyer went directly to one or a few suppliers instead of advertising the contract. Procurement rules allow this only in specific cases, such as extreme urgency, when only one supplier can do the work, or for call-offs from an existing framework.

What “without competition” means

Buyer
The Royal Marsden NHS Foundation Trust · Body governed by public law
Supplier
Advanced Accelerator Application
Value
£4,500,000
Procedure
Award procedure without prior publication of a call for competition
Sector
Medical equipment & pharmaceuticals · Pharmaceutical products (CPV 33600000)
Region
London
Official notice
001348-2021 on Find a Tender
Timeline
  1. Contract date22 Jan 2021
  2. Published22 Jan 2021Published the same day

Description

The Royal Marsden Hospital NHS Foundation Trust needs to purchase 177Lu- Dotatate (Lutathera ®) to treat patients with neuroendocrine tumours

About the supplier

More from The Royal Marsden NHS Foundation Trust

All contracts

Recent medical equipment & pharmaceuticals contracts

Sector overview